NASDAQ:PAHC

Phibro Animal Health Stock Forecast, Price & News

$21.63
+0.23 (+1.07 %)
(As of 09/21/2021 12:52 PM ET)
Add
Compare
Today's Range
$21.41
$21.63
50-Day Range
$21.31
$25.68
52-Week Range
$16.27
$31.00
Volume616 shs
Average Volume135,062 shs
Market Capitalization$876.10 million
P/E Ratio16.14
Dividend Yield2.22%
Beta0.51
30 days | 90 days | 365 days | Advanced Chart
Receive PAHC News and Ratings via Email

Sign-up to receive the latest news and ratings for Phibro Animal Health and its competitors with MarketBeat's FREE daily newsletter.


Phibro Animal Health logo

About Phibro Animal Health

Phibro Animal Health Corp. engages in the manufacture and supply of animal health and mineral nutrition products. It operates through the following segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment develops and markets antibacterial, nutritional specialty products, and vaccines. The Mineral Nutrition segment comprises of the formulations and concentrations of trace minerals such as zinc, manganese, copper, iron, and compounds. The Performance Products segment produces specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was founded on May 11, 1946 and is headquartered in Teaneck, NJ.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.51 out of 5 stars

Medical Sector

100th out of 1,352 stocks

Pharmaceutical Preparations Industry

45th out of 665 stocks

Analyst Opinion: 0.5Community Rank: 4.1Dividend Strength: 2.5Insider Behavior: 4.2Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Phibro Animal Health (NASDAQ:PAHC) Frequently Asked Questions

Is Phibro Animal Health a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Phibro Animal Health in the last twelve months. There are currently 2 sell ratings for the stock. The consensus among Wall Street research analysts is that investors should "sell" Phibro Animal Health stock.
View analyst ratings for Phibro Animal Health
or view top-rated stocks.

What stocks does MarketBeat like better than Phibro Animal Health?

Wall Street analysts have given Phibro Animal Health a "Sell" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Phibro Animal Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Phibro Animal Health's next earnings date?

Phibro Animal Health is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Phibro Animal Health
.

How were Phibro Animal Health's earnings last quarter?

Phibro Animal Health Co. (NASDAQ:PAHC) released its earnings results on Tuesday, August, 24th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.31 by $0.01. Phibro Animal Health had a trailing twelve-month return on equity of 23.68% and a net margin of 6.53%.
View Phibro Animal Health's earnings history
.

How has Phibro Animal Health's stock been impacted by Coronavirus (COVID-19)?

Phibro Animal Health's stock was trading at $24.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PAHC stock has decreased by 12.3% and is now trading at $21.55.
View which stocks have been most impacted by COVID-19
.

How often does Phibro Animal Health pay dividends? What is the dividend yield for Phibro Animal Health?

Phibro Animal Health declared a quarterly dividend on Monday, July 26th. Investors of record on Wednesday, September 1st will be paid a dividend of $0.12 per share on Wednesday, September 22nd. This represents a $0.48 annualized dividend and a dividend yield of 2.23%. The ex-dividend date of this dividend is Tuesday, August 31st.
View Phibro Animal Health's dividend history
.

Is Phibro Animal Health a good dividend stock?

Phibro Animal Health pays an annual dividend of $0.48 per share and currently has a dividend yield of 2.22%. Phibro Animal Health does not yet have a strong track record of dividend growth. The dividend payout ratio of Phibro Animal Health is 38.71%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Phibro Animal Health will have a dividend payout ratio of 36.09% next year. This indicates that Phibro Animal Health will be able to sustain or increase its dividend.
View Phibro Animal Health's dividend history.

What guidance has Phibro Animal Health issued on next quarter's earnings?

Phibro Animal Health issued an update on its FY 2022 earnings guidance on Wednesday, September, 15th. The company provided EPS guidance of $1.250-$1.320 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.340. The company issued revenue guidance of $840 million-$870 million, compared to the consensus revenue estimate of $850.23 million.

What price target have analysts set for PAHC?

2 analysts have issued twelve-month price objectives for Phibro Animal Health's shares. Their forecasts range from $22.00 to $23.00. On average, they expect Phibro Animal Health's share price to reach $22.50 in the next year. This suggests a possible upside of 4.4% from the stock's current price.
View analysts' price targets for Phibro Animal Health
or view top-rated stocks among Wall Street analysts.

Who are Phibro Animal Health's key executives?

Phibro Animal Health's management team includes the following people:
  • Jack C. Bendheim, Chairman, President & Chief Executive Officer
  • Larry L. Miller, Chief Operating Officer
  • Damian Finio, Chief Financial Officer
  • Thomas G. Dagger, Secretary, Senior Vice President & General Counsel
  • Daniel M. Bendheim, Director & Executive VP-Corporate Strategy

What is Jack Bendheim's approval rating as Phibro Animal Health's CEO?

4 employees have rated Phibro Animal Health CEO Jack Bendheim on Glassdoor.com. Jack Bendheim has an approval rating of 100% among Phibro Animal Health's employees. This puts Jack Bendheim in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Phibro Animal Health's key competitors?

What other stocks do shareholders of Phibro Animal Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phibro Animal Health investors own include Zynga (ZNGA), Trevena (TRVN), Endo International (ENDP), Sonoma Pharmaceuticals (SNOA), Zynerba Pharmaceuticals (ZYNE), Intercept Pharmaceuticals (ICPT), VIVUS (VVUS), Zoetis (ZTS), Banco Bradesco (BBD) and Booking (BKNG).

What is Phibro Animal Health's stock symbol?

Phibro Animal Health trades on the NASDAQ under the ticker symbol "PAHC."

Who are Phibro Animal Health's major shareholders?

Phibro Animal Health's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.38%), Vanguard Group Inc. (5.54%), Pzena Investment Management LLC (3.11%), State Street Corp (1.92%), Principal Financial Group Inc. (1.80%) and Renaissance Technologies LLC (1.64%). Company insiders that own Phibro Animal Health stock include E Thomas Corcoran and Larry Lee Miller.
View institutional ownership trends for Phibro Animal Health
.

Which major investors are selling Phibro Animal Health stock?

PAHC stock was sold by a variety of institutional investors in the last quarter, including Cove Street Capital LLC, BlackRock Inc., Smith Graham & Co. Investment Advisors LP, Renaissance Technologies LLC, Nuveen Asset Management LLC, AQR Capital Management LLC, Marshall Wace LLP, and Marshall Wace LLP.
View insider buying and selling activity for Phibro Animal Health
or view top insider-selling stocks.

Which major investors are buying Phibro Animal Health stock?

PAHC stock was bought by a variety of institutional investors in the last quarter, including Amundi, Pzena Investment Management LLC, Invesco Ltd., FMR LLC, Morgan Stanley, Morgan Stanley, Wells Fargo & Company MN, and First Trust Advisors LP.
View insider buying and selling activity for Phibro Animal Health
or or view top insider-buying stocks.

How do I buy shares of Phibro Animal Health?

Shares of PAHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Phibro Animal Health's stock price today?

One share of PAHC stock can currently be purchased for approximately $21.55.

How much money does Phibro Animal Health make?

Phibro Animal Health has a market capitalization of $872.86 million and generates $833.40 million in revenue each year. The company earns $54.38 million in net income (profit) each year or $1.24 on an earnings per share basis.

How many employees does Phibro Animal Health have?

Phibro Animal Health employs 1,700 workers across the globe.

What is Phibro Animal Health's official website?

The official website for Phibro Animal Health is www.pahc.com.

Where are Phibro Animal Health's headquarters?

How can I contact Phibro Animal Health?

Phibro Animal Health's mailing address is GLENPOINTE CENTRE EAST 3RD FLOOR 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ, 07666. The company can be reached via phone at (201) 329-7300 or via email at [email protected].


This page was last updated on 9/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.